AI Article Synopsis
- Despite advances in cancer treatment, colorectal cancer (CRC) remains the third leading cause of cancer deaths, largely due to resistance to therapy and disease recurrence in patients.
- Research indicates that disruptions in hormone signaling and its interaction with other pathways may contribute to this resistance in CRC cells.
- This review explores the role of microRNAs (miRNAs) in hormone signaling related to drug resistance in CRC, highlighting their potential as targets for future treatments.
Article Abstract
Despite substantial progress in cancer therapy, colorectal cancer (CRC) is still the third leading cause of cancer death worldwide, mainly due to the acquisition of resistance and disease recurrence in patients. Growing evidence indicates that deregulation of hormone signaling pathways and their cross-talk with other signaling cascades inside CRC cells may have an impact on therapy resistance. MicroRNAs (miRNAs) are small conserved non-coding RNAs thatfunction as negative regulators in many gene expression processes. Key studies have identified miRNA alterations in cancer progression and drug resistance. In this review, we provide a comprehensive overview and assessment of miRNAs role in hormone signaling pathways in CRC drug resistance and their potential as future targets for overcoming resistance to treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823834 | PMC |
| http://dx.doi.org/10.3390/cells10010039 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!